After both renal and hepatic evaluations, it was concluded that no hepatic or renal dosing adjustments are necessary with liraglutide
Methods Data sources and search strategy This systematic review was conducted up to 01 December 2024 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines
How to Choose Your Food Tracking App Step 1: Identify Your Main Goal Are you tracking for weight loss
Whether youre interested in how to microdose GLP-1 for perimenopause, autoimmune support, or general metabolic optimization, our providers can help determine the right approach for you

Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following: Persistent or severe vomiting that prevents adequate fluid or food intake Signs of dehydration , including dizziness, reduced urination, or extreme thirst Severe or persistent abdominal pain , which may rarely indicate pancreatitis or a gallbladder problem Right upper quadrant pain, fever, or jaundice , which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) a recognised risk with GLP-1-based therapies and with rapid weight loss [11] [12] Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion Injection site reactions that are worsening, infected, or not resolving Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available

Eid RA, Zaki MSA, Alaa Eldeen M, Alshehri MM, Shati AA, El-Kott AF